#USA #NVIDIA #GenScript #Piscataway #AI Biotech

GenScript Launches Life Sciences Startup PitchFest with NVIDIA

In an exciting development for the biotechnology sector, GenScript Biotech Corporation has announced the launch of the Life Sciences Startup PitchFest in collaboration with NVIDIA. This inaugural competition is set to take place during JPM Week in January and aims to accelerate the integration of artificial intelligence in therapeutic discoveries.

The primary objective of this PitchFest is to connect emerging AI-driven life sciences startups with essential resources, including validation expertise from GenScript, investment opportunities, and potential ecosystem partnerships provided by NVIDIA. Startups specializing in various technologies, such as AI-assisted drug design and life sciences applications, are encouraged to participate and submit their applications starting now.

Key Components of the PitchFest

Selected finalists, up to six in total, will showcase their innovations during a pitch event hosted by GenScript. A panel of seasoned judges will evaluate the presentations, and the winning startup will be granted GenScript wet lab data credits alongside Brev credits from NVIDIA to help them fuel their development journeys.

This initiative underscores the increasing role of AI in therapeutic discovery, which allows for quicker generation of hypotheses, target identification, and candidate design. By catalyzing this momentum, GenScript and NVIDIA aim to facilitate a direct connection between innovative companies and investors, ensuring that promising computational predictions are met with biological validation in a cohesive and efficient manner.

Ray Chen, President of GenScript's Life Science Group, emphasizes the importance of creating an ecosystem where cutting-edge computation is paired with reliable biological validation. He states, “Success in this space requires a connected pathway that brings together data, experimental evidence, and investment to help innovators move with confidence.” The PitchFest is envisioned as a vital platform for digital biology startups, offering them integrated support to quickly validate their models, gather evidence, and fast-track the development of breakthrough therapies.

The Role of GenScript and NVIDIA

GenScript will leverage its robust sequence-to-data capabilities and experimental validation expertise, while NVIDIA will open the doors to its Inception program, which assists startups in scaling and connecting within its expansive platform. By merging these resources, both companies aim to help startups transition from potential AI concepts to viable biological proofs and investor-ready projects.

Finalists will also be welcomed to participate in GenScript's Biotech Global Forum, which offers an opportunity to network and engage with key biotechnology executives, strategic partners, and distinguished leaders in the field of AI-enabled discoveries. This access could prove invaluable for startups looking to solidify their place in the biotech landscape and elevate their commercial strategies.

In the weeks leading up to the PitchFest, more details are expected to be released, including information on judging criteria, participating speakers, and investor involvement. This initiative not only emphasizes the innovative potentials available in the biotech field but also highlights the growing importance of AI in revolutionizing therapeutic development.

About GenScript

Founded in 2002 in New Jersey, GenScript Biotech Corporation empowers researchers and biotech companies by providing the necessary building blocks for groundbreaking treatments and products. With a mission to enhance global health through biotechnology, GenScript has established itself as a trusted partner within the life sciences ecosystem, boasting a skilled workforce of over 6,100 individuals, and supporting more than 200,000 customers globally, including the top 20 pharmaceutical companies.

For additional information about participation in the PitchFest and other initiatives, you can visit GenScript for details.